) has been revised to $8.36 / share. This is an increase of 26.15% from the prior estimate of $6.63 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...

) has been revised to $11.37 / share. This is an increase of 11.43% from the prior estimate of $10.20 dated March 25, 2026. The price target is an average of many targets provided by analysts. The ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ocugen (NASDAQ:OCGN) is in the spotlight in Healthcare Stocks after a fresh development. Here is what changed, why it matters, and what to watch next.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

An announcement from Ocugen ( ) is now available. On September 21, 2026, Ocugen, Inc. held a virtual Special Meeting of Stockholders at which 160,214,431 shares, representing 47.3 ...

Ocugen (OCGN) is a clinical-stage biotech focused on modifier gene therapies for inherited retinal diseases, with key catalysts expected by 2026. OCGN's pipeline includes OCU400 (RP/LCA), OCU410ST ...

Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.05 per share a year ago. These figures are ...

Ocugen, Inc. announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel ...

Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapies Expands access ...

Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 25.6% to $2.06 during Monday’s session. The stock is trading higher, potentially on upward momentum, after the Third Circuit Court of Appeals last ...